More data support efficacy of GEN-003 therapeutic vaccine for HSV-2 - Healio

UPI.com

More data support efficacy of GEN-003 therapeutic vaccine for HSV-2 Healio BOSTON — Three doses of a novel therapeutic DNA vaccine for genital herpes reduced viral shedding and genital lesion formation, according to results from a phase 2 clinical trial. The effect of the regimen appears to last for up to 1 year, researchers ... A novel therapy for genital herpes engages immune cells to provide significant patient benefitsMedical Xpress NanoViricides Reports On Progress of Its Drug Candidates against HerpesvirusesPR Newswire (press release) Vical's Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes ...Virtual-Strategy Magazine all 7 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNF8147KTt_RwByi7q3lMA1QW1gt8Q&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779136119223&ei=tzdoV4DPOcSA3QGIqIGgDQ&url=http://www.healio.com/infectious-disease/stds/news/online/%257Bad0d64d3-9917-4014-8187-9241b2532247%257D/more-data-support-efficacy-of-gen-003-therapeutic-vaccine-for-hsv-2
via IFTTT